Mindrug Biologics Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
- Paid Up Capital ₹ 1.50 Cr
- Company Age 2 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 18.46 Cr
About Mindrug Biologics
Mindrug Biologics Private Limited (MBPL) is a Private Limited Indian Non-Government Company incorporated in India on 01 August 2022 (Two years and six months 5 days old ). Its registered office is in Mohali, Punjab, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 1.50 Cr.
The company currently has active open charges totaling ₹18.46 Cr.
Gurkaranjit Sodhi, Kulpreet Sodhi, and Swaranjit Sodhi serve as directors at the Company.
Company Details
-
Location
Mohali, Punjab, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24100PB2022PTC056582
-
Company No.
056582
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
01 Aug 2022
-
Date of AGM
16 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Chandigarh
Industry
Who are the key members and board of directors at Mindrug Biologics?
Board Members (3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gurkaranjit Sodhi
|
Director | 01-Aug-2022 | Current |
|
Kulpreet Sodhi
|
Director | 01-Aug-2022 | Current |
|
Swaranjit Sodhi
|
Director | 01-Aug-2022 | Current |
Financial Performance of Mindrug Biologics.
Mindrug Biologics Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mindrug Biologics?
Unlock access to Mindrug Biologics's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
₹18.46 Cr
₹0
Charges Breakdown by Lending Institutions
- Canara Bank : 18.46 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 09 Oct 2024 | Canara Bank | ₹3.00 Cr | Open |
| 09 Oct 2024 | Canara Bank | ₹15.46 Cr | Open |
How Many Employees Work at Mindrug Biologics?
Mindrug Biologics has a workforce of 0 employees as of Apr 08, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mindrug Biologics, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mindrug Biologics's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
